Palvella reports positive bleeding results from rapamycin trial

May 15, 2026 7:30 AM

Palvella Therapeutics Inc. (NASDAQ: PVLA) announced new data from its Phase 2 TOIVA trial showing that all patients with baseline ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found